New protein treatment for inflammatory bowel disease
Official title: Aim protein-based anti-inflammatory therapeutic for the treatment of IBD
Funded at Keybiome INC · NIH-11176728 · Data updated 2026-11-12
This study is testing a new protein from zebrafish that could help people with inflammatory bowel disease (IBD), like ulcerative colitis and Crohn’s disease, by reducing inflammation and improving gut health, and you might have a chance to join the trials to see how well it works!
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Keybiome INC NIH-funded |
| Lab location | 1 site (Eugene, UNITED STATES) |
| Project start | September 19, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $228,408 |
| NIH project number | 6R41DK138693-02 |
| Project ID | NIH-11176728 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with inflammatory bowel disease, particularly those experiencing severe symptoms or inadequate response to current treatments.
✕Less likely to help
Patients with IBD who are currently in remission or those who do not have a diagnosis of inflammatory bowel disease may not benefit from this research.
What this research studies
This research investigates a novel anti-inflammatory protein derived from a zebrafish gut symbiont to treat inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn’s disease. The approach aims to address both the inflammation and the dysbiosis of the intestinal microbiome that often accompanies these conditions. By targeting the excessive neutrophilic response in the colonic tissues, the treatment seeks to provide a more effective solution than current therapies, which have significant side effects. Patients may have the opportunity to participate in trials that evaluate the safety and efficacy of this innovative therapeutic.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment for IBD that reduces inflammation and restores a healthy gut microbiome.
How similar studies have gone: While the approach of using a protein from a gut symbiont is innovative, similar strategies targeting microbiome dysbiosis in IBD have shown promise in preliminary studies.
Where this research is happening
-
Keybiome INC
Eugene, United States Active
Researchers
- Principal investigator: Pohl Robinson, Catherine — Keybiome INC
- Study coordinator: Pohl Robinson, Catherine
Related research
Other NIH-funded projects on the same topics.
-
Aim protein-based anti-inflammatory therapy for inflammatory bowel disease (IBD)
A new oral protein medicine called AimA is being developed to ease inflammation and restore balance in the gut for adults with IBD.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.